The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
The last time I spoke about Absci Corporation (ABSI), it was in a Seeking Alpha article entitled "Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile." The hope here ...
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...
Fifth-generation AMD EPYC processors and RDMA cluster networking power OCI’s bare metal instances. They provide Absci with the low-latency networking and throughput required for large-scale model ...
Absci CEO Sean McClain Absci says it is about a year away from its lead AI-designed therapeutic entering the clinic—one of several pipeline candidates whose development the company says it will be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results